Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • How Disruption in the Strait of Hormuz Can Move Markets Fast

    The Strait of Hormuz is more than an oil chokepoint—disruptions can ripple through energy markets, food inputs, and critical materials worldwide.

    Read more

  • Natera, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Natera, Inc. (NTRA $193.03), a leader in cell-free DNA (cfDNA) test for oncology, women’s health, and organ health.

    Read more

  • A Business Owner’s Guide to the Spectrum of Liquidity Options

    Explore liquidity options for founders. From dividend recaps to strategic sales, learn to balance post-transaction control with your short and long-term goals.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures